Two truncated peptides, Gj-CATH3-(38–42)-peptide and Gj-CATH3-(33–42)-peptide induced HaCaT cell proliferation and prevent decreases in SOD activity and increases of MDA concentration in injured-skin tissue.
[European Journal of Pharmacology]
6807162 PV5DA4K9 items 1 apa default asc 1
Derivatives of gecko cathelicidin-related antioxidant peptide facilitate skin wound healing - ScienceDirect. (n.d.). Retrieved October 16, 2020, from https://www.sciencedirect.com/science/article/abs/pii/S001429992030741X?via%3Dihub Cite
Researchers undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate), MBT-2 (bladder) and Renca (kidney) were used.
6630899 PH5DPRPV items 1 apa default asc 1
Kunimura, N., Kitagawa, K., Sako, R., Narikiyo, K., Tominaga, S., Bautista, D. S., Xu, W., Fujisawa, M., & Shirakawa, T. (2020). Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Scientific Reports, 10(1), 17464. https://doi.org/10.1038/s41598-020-74660-2 Cite
Long non-coding RNA small nucleolar host gene 11 (SNHG11) post-transcriptionally upregulated catenin beta 1 and autophagy related 12 through miR-483-3p/miR-1276, while the processing of pre-miR-483/pre-miR-1276 was hindered by SNHG11. SNHG11 induced GSK-3β ubiquitination through interacting with Cullin 4A to further activate the Wnt/β-catenin pathway.
6606345 V2D36J4D items 1 apa default asc 1
LncRNA SNHG11 promotes gastric cancer progression by activating Wnt/β-catenin pathway and oncogenic autophagy: Molecular Therapy. (n.d.). Retrieved October 15, 2020, from https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30545-1 Cite
Dp71ab, but not Dp71, was found to be a molecular enhancer of myoblast proliferation and transfection with Dp71ab may generate a high yield of stem cells for Duchenne muscular dystrophy treatment.
6630899 CCXSYUT4 items 1 apa default asc 1
Scientists demonstrated a unique role for liver in modulating the pathogenesis of leukemic disease and suggest that the hepatic microenvironment may protect leukemia cells from chemotherapeutic challenge.
6630899 4D9N2Y6L items 1 apa default asc 1
The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG | Cancer Discovery. (n.d.). Retrieved October 13, 2020, from https://cancerdiscovery.aacrjournals.org/content/early/2020/10/07/2159-8290.CD-20-0318 Cite
Investigators evaluated the potential anti-tumor effect of Tideglusib, an irreversible glycogen synthase kinase (GSK)-3β inhibitor drug, on three human neuroblastoma cell lines, SK-N-SH, SH-SY5Y, and IMR-32.
6445212 G323FDFF items 1 apa default asc 1
Bahmad, H. F., Chalhoub, R. M., Harati, H., Bou-Gharios, J., Assi, S., Ballout, F., Monzer, A., Msheik, H., Araji, T., Elajami, M. K., Ghanem, P., Chamaa, F., Kadara, H., Abou-Antoun, T., Daoud, G., Fares, Y., & Abou-Kheir, W. (2020). Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β. Pharmacological Reports. https://doi.org/10.1007/s43440-020-00162-7 Cite
Oncogenic function of RNase7 was analyzed by cell proliferation, migration, invasion assays and xenograft mouse model. The anti-ROS1 inhibitor treatment efficacy was evaluated in hepatocellular carcinoma patient-derived xenograft and orthotopic models.
[Journal of Hepatology]
6445212 S4LCZPU9 items 1 apa default asc 1
Liu, C., Zha, Z., Zhou, C., Chen, Y., Xia, W., Wang, Y.-N., Lee, H.-H., Yin, Y., Yan, M., Chang, C.-W., Chan, L.-C., Qiu, Y., Li, H., Li, C.-W., Hsu, J.-M., Hsu, J. L., Wang, S.-C., Ren, N., & Hung, M.-C. (2020). Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology, 0(0). https://doi.org/10.1016/j.jhep.2020.09.030 Cite
Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1+ B-cell lymphoma.
[Clinical Cancer Research]
6445218 KJJHYBZ7 items 1 apa default asc 1
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., Lu, Z., & Qian, W. (2020). CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-1457 Cite
In vitro studies using human dermal fibroblasts and diabetes mellitus fibroblasts and an in ovo chorioallantoic membrane assay confirmed that the Alg-PDRN hydrogel effectively induced cell proliferation and expression of angiogenic growth factors and promoted new blood vessel formation.
Investigators showed that the combination of Rho-associated kinase (ROCK) inhibition with Ca2+ elevation regulated the phosphorylation of myosin light chain II and improved both cell expansion and cell–cell adhesion during the culture of human nasal mucosal epithelial cell sheets.
6807162 K5SSJZB2 items 1 apa default asc 1
ROCK inhibitor combined with Ca 2+ controls the myosin II activation and optimizes human nasal epithelial cell sheets | Scientific Reports. (n.d.). Retrieved October 8, 2020, from https://www.nature.com/articles/s41598-020-73817-3 Cite
Enforced ARHGEF19 expression promotes small cell lung cancer cell proliferation in vitro and its knockdown decreases cell proliferation in vitro and in vivo.
[Biochemical and Biophysical Research Communications]
1254621 TYC8LJHR items 1 apa default asc 1